主な業績

• Senoo K, Kondo Y, Kobayashi Y, Lip GY. Silent Cerebral Infarction in East Asian vs. Non-Asian Atrial Fibrillation Patients　- Meta-Analysis. Circ J. 2017 Dec 27. doi: 10.1253/circj.CJ-17-1164. [Epub ahead of print]
• Kondo Y, Senoo K, Kobayashi Y. Direct oral anticoagulants for Japanese atrial fibrillation in the elderly. J Cardiol. 2018 Mar;71(3):323-324
• Senoo K, Kondo Y, Miyazawa K, Isogai T, Chun YH, Kobayashi Y. Safety and efficacy of direct oral anticoagulants over warfarin in Japanese patients with acute venous thromboembolism: A meta-analysis. J Cardiol. 2017 May;69(5):763-768.
• Ogawa H, Senoo K, An Y, Shantsila A, Shantsila E, Lane DA, Wolff A, Akao M, Lip GYH. Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. EBioMedicine. 2017 Apr;18:199-203.
• Senoo K, Lip GY. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial. Int J Cardiol. 2016 Oct 15;221:379-82.
• Senoo K, An Y, Ogawa H, Lane DA, Wolff A, Shantsila E, Akao M, Lip GY. Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart. 2016 Dec 1;102(23):1878-1882.
• Senoo K, Lip GY. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin. Stroke. 2016 Jun;47(6):1665-8.
• Proietti M, Senoo K, Lane DA, Lip GY. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep. 2016 Apr 12;6:24376.
• Senoo K, Lip GY. Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial. Stroke. 2016 Feb;47(2):523-6.
• Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin. Am J Med. 2016 Jun;129(6):600-7.
• Senoo K, Lip GY. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial. Stroke. 2015 Nov;46(11):3202-7.
• Senoo K, Lip GY, Lane DA, Büller HR, Kotecha D. Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. Stroke. 2015 Sep;46(9):2523-8.
• Senoo K, Lip GY. Switching from a vitamin K antagonist to a NOAC. The Lancet Haematology. 2015 April 2, No. 4, e132–e133.
• Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail. 2015 Nov;17(11):1192-200.
• Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. Int J Cardiol. 2015 Sep 15;195:237-42.
• Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol. 2015 Jul 15;191:172-7
• Senoo K, Lip GY. Not all thromboembolism comes from the left atrial appendage in atrial fibrillation. Heart. 2015 Jun 1;101(11):830-1.
• Senoo K, Lip GY. Comparative Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation. Semin Thromb Hemost. 2015 2015 Mar;41(2):146-53.
• Senoo K, Lane DA, Lip GY. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. Int J Cardiol. 2014 Dec 5;181C:247-254.
• Senoo K, Lau YC, Dzeshka M, Lane D, Okumura K, Lip GY. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation. Circ J. 2015;79(2):339-45.
• Senoo K, Lip GY. Prediction of stroke in patients without atrial fibrillation using the CHADS2 and CHA2DS2-VASc scores: a justification for more widespread thromboprophylaxis? Heart. 2014 Oct;100(19):1485-6.
• Senoo K, Lau YC, Lip GY. Updated NICE guideline: management of atrial fibrillation (2014). Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1037-40
• Senoo K, Lane DA, Lip GY. Oral anticoagulants for stroke prevention in atrial fibrillation. Curr Probl Cardiol. 2014 Sep;39(9):319-44.
• Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014 Sep;44(5):281-90
• Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, Uejima T, Oikawa Y, Yajima J, Nagashima K, Kirigaya H, Sawada H, Aizawa T and Yamashita T. Progression into persistent form in asymptomatic patients with paroxysmal atrial fibrillation. Circ J 2014;78(5):1121-6.
• Senoo K, Otsuka T, Suzuki S, Sagara K and Yamashita T. Impact of pulmonary vein isolation on complete left bundle branch block following tachycardia induced cardiomyopathy in patient with persistent atrial fibrillation. Intern Med 2014;53(7):721-4.
• Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Lip GY and Yamashita T. Coronary artery diseases in patients with Japanese nonvalvular atrial fibrillation. J Cardiol 2014;63(2):123-7
• Senoo K, Otsuka T, Suzuki S, Sagara K and Yamashita T. A case of premature ventricular contractions originating from the papillary muscle in the right ventricle. J of Arrhythmia 2014;30(3):192-196
• Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T and Yamashita T. Distribution of first-detected atrial fibrillation patients without structural heart diseases in symptom classifications. Circ J 2012;76(4):1020-3.